Welcome from the Division Chief
Welcome to the website for the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University. We are incredibly proud of our tradition and accomplishments in contributing to the advancement of treatment of infectious diseases locally, nationally and worldwide.
Our core mission is to heal, to teach and to discover. Facing the challenges of emerging and re-emerging infectious diseases at home and across the globe; we pride ourselves on delivering the highest quality of care for our patients, providing exceptional fellowship training to the next generation of Infectious Diseases physicians and continuing to make scientific breakthroughs through our world renowned research.
Passion for Healthy Travel Inspires Generous Gift for Travel Medicine Clinic
A generous gift from UH benefactor and frequent traveler Roe Green (left) will help keep travelers safe here and abroad.
Philanthropist Roe Green is a world traveler, visiting more than 160 countries in her lifetime. Her passion for travel has inspired a generous $5 million gift to University Hospitals and the Division of Infectious Diseases that will help keep globe-trotting patients healthy.
Roe Green has had a lifelong passion for travel and began going overseas with her parents as a teenager. In preparation for these trips, she always has relied on UH’s travel medicine clinic as an important resource to stay healthy before, during and after her journeys. She has visited more than 160 countries and feels travel is an important educational tool.
One of the first of its kind in the country, the Roe Green Center for Travel Medicine serves about 4,500 travelers each year through clinics at UH Case Medical Center and UH Chagrin Highlands and Westlake health centers. International travelers – including those bound for developing countries that present special health risks – receive comprehensive preventive care, vaccines and education. UH physicians also help travelers with complex pre-existing conditions to manage their medical needs while abroad. In addition, UH is among the first U.S. providers to care for the special needs of students and children traveling overseas through its child travelers and adoption clinic at UH Rainbow Babies & Children’s Hospital.
Ms. Green’s gift will allow UH’s newly named Roe Green Center for Travel Medicine to provide targeted support for facilities, programs and physician-scientists in travel medicine, including renowned infectious disease specialists Robert Salata, MD and Keith Armitage, MD. UH also will enhance educational experiences for trainees in the internal medicine residency and infectious diseases fellowship, and provide continuing medical education lectures for physicians.
Dr. Bonomo receives 2015 Harrington Scholar-Innovator Award
Congratulations to Robert Bonomo, MD for being selected a 2015 Harrington Scholar-Innovator Award Recipient for his work in drug-resistant infections.
The Harrington Discovery Institute at University Hospitals is extending its reputation as a driving force for breakthrough medical therapies by adding 11 leading physician-scientists as 2015 Harrington Scholar-Innovators.
These Harrington Scholar-Innovators join 28 prominent investigators who have earned drug-development support from The Harrington Discovery Institute since it was established in 2012. The Harrington Discovery Institute has become the catalyst for a new international model that aligns for-profit and nonprofit resources to create a dedicated system for drug development.
The Harrington Discovery Institute Scientific Advisory Board selects Harrington Scholar-Innovators after a rigorous review of proposals from physician-scientists at academic medical centers across the country. They receive grants of up to $700,000 ($100,000 guaranteed) to continue their research at their own organizations. In addition, the Scholar-Innovators gain access to the Harrington Discovery Institute’s Innovation Support Center, which provides expert oversight to help them transform their discoveries into new drug therapies.
Dr. Carlos Subauste Receives National Innovation Award
From National Center for Accelerated Innovations
Innovation is a skill in high demand in academic medicine. The National Center for Accelerated Innovation (NCAI), a grant program funded by the NIH and managed as a partnership between the Cleveland Clinic, CWRU, UH Case Medical Center, and institutions across the state, recently awarded funds to Dr. Carlos Subauste to help accelerate promising technologies developed in his laboratory. The NIH’s Heart Lung and Blood Institute developed the NCAI program to increase the generation of new, patient benefiting products related to priority targets in the heart, lung, blood and sleep disorders space. The Ohio consortium has established an efficient infrastructure to propel early-stage projects forward and to engage and educate researchers to be full partners in transforming their discoveries into high-impact advances in patient care.
Dr. Subauste is Associate Professor of Medicine, Ophthalmology and Pathology and an infectious disease specialist with UH Case Medical Center. His research is focused on inhibition of CD40-TRAF signaling for the treatment of vascular inflammatory disorders, and he will use his award to synthesize and test the CD40-TRAF inhibitor in pre-clinical models of inflammation. His award will be matched by funds from the Council to Advance Human Health Accelerator Fund.
Common herpes medication reduces HIV-1 levels, independent of herpes infection
Case Western Reserve researchers play key role in clinical trials’ groundbreaking results
Case Western Reserve University researchers are part of an international team that discovered that a common herpes drug reduces HIV-1 levels—even when patients do not have herpes.
Published online in Clinical Infectious Diseases, the finding rebuts earlier scientific assumptions that Valacyclovir (brand name, Valtrex) required the presence of the other infection to benefit patients with HIV-1.
The result not only means that Valacyclovir can be used effectively with a broader range of HIV-1 patients, but also suggests promising new avenues for the development of HIV-fighting drugs. This insight is particularly significant given that some forms of HIV-1 have become resistant to existing medications. Read more...